Skip to main content

Advertisement

SpringerLink
Log in

The possible role of burden of therapy on the risk of myeloma extramedullary spread

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Extramedullary relapse (EMR) represents a poor prognostic marker in the course of multiple myeloma (MM). We reviewed data from 329 patients, diagnosed between 2000 and 2010, without extramedullary disease at onset to explore possible risk factors for EMR. The median overall survival of our study cohort was 6.4 years. The risk of EMR was 28 % with a median time from diagnosis to first EMR of 2.2 years (0.2–9.1 years). Patients with soft tissue masses located in extra-osseous organs (EMR-S) showed the worst outcome, compared to those with tumor masses arising from adjacent bone (EMR-B) (median OS 1.6 vs 2.4 years, p = 0.006). In addition, patients with EMR-S showed a significant trend for further development of extramedullary masses in a very short time (3.7 vs 5.7 months for EMR-B, p = 0.043). Multivariate analysis failed to identify any clinically presenting features predictive for EMR. The occurrence of EMR was higher in patients with more complex treatment history, defined on the basis of longer treatment duration (≥6 vs <6 months) and on elevated number of treatment lines administered (>2 vs ≤2 lines) (HR = 4.5, p < 0.001 and HR = 9.0, p < 0.001, respectively, when one or both factors are present).In conclusion, increasing burden of treatment might be a possible risk factor for EMR. MM patients with multiple relapses should be comprehensively investigated including, when possible, a whole-body-targeted radiologic technique to accurately detect EMR. Treatment choice should take into account the very poor outcome for patients with soft tissue involvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021–1030

    Article  CAS  PubMed  Google Scholar 

  2. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370:1209–1218

    Article  CAS  PubMed  Google Scholar 

  3. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917

    Article  CAS  PubMed  Google Scholar 

  4. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621–4629

    Article  CAS  PubMed  Google Scholar 

  5. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29–37

    Article  CAS  PubMed  Google Scholar 

  6. Kumar S, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Martinez-Lopez J, Bladè J, Mateos MV, Grande C, Alegre A, Garcia-Larana J et al (2011) Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118:529–534

    Article  CAS  PubMed  Google Scholar 

  8. Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez R, Powles R et al (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29:3805–3812

    Article  PubMed  Google Scholar 

  9. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21:325–330

    Article  CAS  PubMed  Google Scholar 

  10. Weinstock M, Ghobrial I (2013) Extramedullary multiple myeloma. Leuk Lymphoma 54:1135–1141

    Article  PubMed  Google Scholar 

  11. Wirk B, Wingard JR, Moreb JS (2013) Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. Bone Marrow Transplant 48:10–18

    Article  CAS  PubMed  Google Scholar 

  12. Moreau P, Polliack A (2013) Extramedullary multiple myeloma: extra-osseous relapse is extra “bad news”, but why? Leuk Lymphoma 54:1349–1350

    Article  PubMed  Google Scholar 

  13. Papanikolaou X, Repousis P, Tzenou T, Maltezas D, Kotsopoulou M, Megalakaki K et al (2013) Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma 54:1459–1464

    Article  CAS  PubMed  Google Scholar 

  14. Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A et al (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97:1761–1767

    Article  PubMed  PubMed Central  Google Scholar 

  15. Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A et al (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25:906–908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L et al (2014) Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 99:360–417

    Article  PubMed  PubMed Central  Google Scholar 

  17. Fernandez de Larrea C, Jimenez R, Rosinol L, Gine’ L, Tovar N, Cibeira MT et al (2014) Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplant 49(Jimenez R):223–227

    Article  CAS  PubMed  Google Scholar 

  18. Weinstock M, Aljawai Y, Morgan E et al (2015) Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol 169:851–858

    Article  CAS  PubMed  Google Scholar 

  19. Varga C, Wanling X, Laubach J, Ghobrial IM, O’Donnel EK, Weinstock M et al (2015) Development of extramedullary myeloma in the era of novel agent: no evidence of increased risk with lenalidomide-bortezomib combination. Br J Haematol 169:843–850

    Article  CAS  PubMed  Google Scholar 

  20. Blade J, Fernadez de Larrea C, Rosinol L (2015) Extramedullary disease in multiple myeloma in the era of novel agents. Br J Haematol 169:763–765

    Article  PubMed  Google Scholar 

  21. Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P et al (2015) Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Ann Hematol 94:2033–2042

    Article  CAS  PubMed  Google Scholar 

  22. Touzeau C, Moreau P (2016) How I treat extramedullary myeloma. Blood 127(8):971–976

    Article  CAS  PubMed  Google Scholar 

  23. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N et al (2013) Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 121:1819–1823

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zamagni E, Cavo M (2012) The role of imaging techniques in the management of multiple myeloma. Br J Haematol 159:499–513

    PubMed  Google Scholar 

  25. Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R et al (2014) International Myeloma Working Group recommendation for global myeloma care. Leukemia 28:981–992

    Article  CAS  PubMed  Google Scholar 

  26. Mesgnich C, Fardanesh R, Tenembaum L, Chari A, Jagannath S, Kostakoglu L (2014) State of the art imaging in multiple myeloma: comparative review of FDG-PET/CT imaging in various clinical settings. Eur J Rad 63:2203–2223

    Article  Google Scholar 

  27. Tirumani SH, Sakellis C, Jacene H, Shinagare AB, Munshi NC, Ramaiya NH et al (2016) Role of FDG-PET/CT in extramedullary multiple myeloma: correlation of FDG-PET/CT findings with clinical outcome. Clin Nucl Med 41:e7–e13

    Article  PubMed  Google Scholar 

  28. Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L et al (2015) PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res 21(19):4384–4390

    Article  CAS  PubMed  Google Scholar 

  29. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH et al (2013) Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27:780–791

    Article  PubMed  Google Scholar 

  30. Pérez-Simón JA, Sureda A, Fernández-Aviles F, Sampol A, Cabrera JR, Caballero D et al (2006) Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 20:542–545

    Article  PubMed  Google Scholar 

  31. Qu X, Chen L, Qiu H, Lu H, Wu H, Qiu H et al (2015) Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance. Biomed Res Int 2015:787809, Epub 2015 Apr 23

    Article  PubMed  PubMed Central  Google Scholar 

  32. Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481:306–313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12:335–348

    Article  CAS  PubMed  Google Scholar 

  34. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067–1076

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Egan JB, Shi CX, Tembe W, Christoforides A, KJurdoglu A, Sinari S et al (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120:1060–1066

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Magrangeas F, Avet-Loiseau H, Gouraud W, Lode’ L, Decaux O, Godmer P et al (2013) Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27:473–481

    Article  CAS  PubMed  Google Scholar 

  37. Bolli N, Avet-Loiseau H, Wedge DC, Van Lool P, Alexandrov LB, Martincorena I et al (2014) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997

    Article  PubMed  PubMed Central  Google Scholar 

  38. Brioli A, Melchor L, Cavo M, Morgan GJ (2014) The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol 165:441–454

    Article  PubMed  Google Scholar 

  39. Sevcikova S, Paszekova H, Besse L, Sedlarikova L, Kubaczkova V, Almasi M et al (2015) Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159:88–93

    Google Scholar 

Download references

Acknowledgments

SM, AP, FC, MV, CC, MC, and AC performed the research. SM, AC, MC, VF, and CK designed the study participated in the statistical analysis and wrote the paper.

Author information

Authors and Affiliations

  1. Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100, Pavia, Italy

    Silvia Mangiacavalli, A. Pompa, V. Ferretti, F. Cocito, M. Varettoni, C. S. Cartia, M. Cazzola & A. Corso

  2. Service of Biometry and Statistics, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

    C. Klersy

Authors
  1. Silvia Mangiacavalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Pompa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Ferretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Klersy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Cocito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Varettoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. S. Cartia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Cazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Corso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Mangiacavalli.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mangiacavalli, S., Pompa, A., Ferretti, V. et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol 96, 73–80 (2017). https://doi.org/10.1007/s00277-016-2847-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2847-z

Keywords

Search

Navigation